Estrogens, Conjugated
Generic Name: estrogens, conjugated
Brand Names:
Conjugated Estrogens
Conjugated Estrogens Tablets contain a mixture of estrogen salts derived from natural sources, available in strengths of 0.3, 0.45, 0.625, 0.9, and 1.25 mg for oral administration.
Overview
Conjugated Estrogens Tablets contain a mixture of estrogen salts derived from natural sources, available in strengths of 0.3, 0.45, 0.625, 0.9, and 1.25 mg for oral administration.
Uses
Treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause; hypoestrogenism; metastatic breast cancer and androgen-dependent prostate cancer palliation; postmenopausal osteoporosis prevention.
Dosage
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration. Starting dose typically 0.3 mg daily; may be given continuously or cyclically.
Side Effects
Most common adverse reactions (5% or greater) include abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leukorrhea, and vaginal hemorrhage.
Interactions
Inducers of CYP3A4, such as St. John's Wort, phenobarbital, and rifampin, may reduce plasma concentrations of estrogens. Inhibitors like erythromycin may increase concentrations.
Warnings
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA. Estrogen-alone increases endometrial cancer and stroke risk. Estrogens increase the risk of gallbladder disease. Contraindicated with undiagnosed abnormal genital bleeding, breast cancer history, estrogen-dependent neoplasia, active/prior DVT, PE, stroke, or MI, hepatic impairment.
Pregnancy
Conjugated Estrogens Tablets are not indicated for use during pregnancy. Estrogens present in breast milk can reduce milk production.
Frequently Asked Questions
What is Estrogens, Conjugated used for?▼
Treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause; hypoestrogenism; metastatic breast cancer and androgen-dependent prostate cancer palliation; postmenopausal osteoporosis prevention.
What are the side effects of Estrogens, Conjugated?▼
Most common adverse reactions (5% or greater) include abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leukorrhea, and vaginal hemorrhage.
Can I take Estrogens, Conjugated during pregnancy?▼
Conjugated Estrogens Tablets are not indicated for use during pregnancy. Estrogens present in breast milk can reduce milk production.
What are the important warnings for Estrogens, Conjugated?▼
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA. Estrogen-alone increases endometrial cancer and stroke risk. Estrogens increase the risk of gallbladder disease. Contraindicated with undiagnosed abnormal genital bleeding, breast cancer history, estrogen-dependent neoplasia, active/prior DVT, PE, stroke, or MI, hepatic impairment.
Related Medications
Olaparib
olaparib
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
11 DESCRIPTION Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one. The empirical molecular formula for Lynparza is C 24 H 23 FN 4 O 3 and the relative molecular mass is 434.46. It has the following chemical structure: Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility across the physiological pH range.
Dipyridamole
dipyridamole
Platelet Aggregation Inhibitor [EPC]
Dipyridamole is a coronary vasodilator described as 2,6 bis-(diethanolamino)-4,8 dipiperidino-pyrimido-(5,4-d) pyrimidine. The structural formula is: C24H40N8O4 MW 504.63 Dipyridamole Injection, USP is a sterile, odorless, pale yellow liquid which can be diluted in sodium chloride injection or dextrose injection for intravenous administration. Each mL contains 5 mg dipyridamole, USP, 50 mg polyethylene glycol 600 and 2 mg tartaric acid in Water for Injection, USP.
Latanoprostene Bunod Ophthalmic Solution, 0.024%
latanoprostene bunod ophthalmic solution, 0.024%
11 DESCRIPTION Latanoprostene bunod ophthalmic solution, 0.024% is a prostaglandin analog formulated as a sterile topical ophthalmic solution. Latanoprostene bunod ophthalmic solution contains the active ingredient latanoprostene bunod 0.24 mg/mL, the preservative benzalkonium chloride 0.2 mg/mL, and the following inactive ingredients: polysorbate 80, glycerin, EDTA, and water. The formulation is buffered to pH 5.5 with citric acid/sodium citrate.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.